of potential sources of DDI risks for a new molecular entity."/>
Figure 2.1. Potential sources of DDI risks for a new molecular entity.
TABLE 2.1. Overview of key enzymes and transporters at different sites relevant for DDI.
| DDI mechanisms | Liver | Intestine | Kidney | Blood–brain barrier | |
|---|---|---|---|---|---|
| Metabolism | Reversible and time‐dependent inhibition of enzymes | 1CYPs UGT1A1 UGT2B7 | CYP3A4, CYP2C9 CYP2C19 UGT2B7 | — | — |
| Induction of enzymes | CYP1A2 CYP2B6 CYP3A4 2CYP2C | CYP3A4 | — | — | |
| Transporters | Inhibition of uptake transporters | OATP1B1 OATP1B3 OCT1 | OCT1 | OAT1 OAT3 OCT2 | — |
| Inhibition of efflux transporters | P‐gp BCRP 3MRP2 | P‐gp BCRP 3MRP2 | P‐gp BCRP MATE1 MATE2/K 3MRP2 3MRP4 | P‐gp BCRP |
1 Cytochrome P450 isoforms (CYPs) 1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A4, 3A5. If these do not play a role, other CYPs (2A6, 2J2, 4F2, and 2E1), other Phase I enzymes (aldehyde oxidase, carboxylesterase, monoamine oxidase, flavin monooxygenase, xanthine oxidase, and alcohol/aldehyde dehydrogenase), or Phase II enzymes (UDP glucuronosyl transferases or UGTs and sulfotransferases or SULTs) may be important.
2 CYP2C enzymes are induced via activation of pregnane X receptor (PXR) just as CYP3A. Since CYP3A is more sensitive to inducer effect, CYP2C induction may be evaluated, if the drug induces CYP3A. UGTs may be coinduced with CYP3A.
3 Not in current regulatory guidelines.
2.2 DRUG INTERACTIONS MEDIATED BY ENZYMES AND TRANSPORTERS AT VARIOUS SITES
The DDI mechanisms and the enzymes and transporters at various sites recommended for DDI risk assessment by FDA and EMA are summarized in Table 2.1.
The rationale for the significance of enzymes and transporters presented in Table 2.1 are as follows:
High affinity, low‐capacity enzymes like CYPs 2C9, 2C19, and 2D6 are more susceptible for inhibition.
Polymorphic enzymes (CYPs 3A5, 2B6, 2C8, 2C19, 2D6; UGTs 1A1, and 2B7) when involved in DDI could contribute to exaggerated exposure variability in some patients.
Enzymes that are expressed in gut (CYP3A4, UGT2B7, etc.) are exposed to higher perpetrator concentrations during absorption phase and therefore contribution of the gut to the overall DDI risk is considerably high.
Clinically relevant DDIs are rare for UGTs, as many of them are low‐affinity, high‐capacity enzymes with broad substrate specificity. Most interactions involving UGTs are associated with low AUC ratios and mostly confined to UGT2B7, a polymorphic enzyme that is involved in the metabolism of many marketed drugs.
Among transporters, organic anion transporting protein (OATP1B1 and OATP1B3), organic cation transporters (OCT1, OCT2), P‐glycoprotein (P‐gp), and breast cancer resistance protein (BCRP) are polymorphic.
Many statins rely on OATP1B1 for their uptake into liver. They are likely to be victims of DDI, when coadministered with OATP1B1 inhibitors. Due to their widespread use, high probability of comedication, and the risk of myalgia and rhabdomyolysis with increased exposure, statins attract considerable interest with respect to DDI.
Among the efflux transporters, interactions with P‐gp are the most studied. Inhibition of P‐gp may not result in clinically significant differences in the exposure of the victim drug, but it can attenuate the efficacy of drugs targeting barrier tissues such as brain, lymphocytes, and tumor.
2.3 FACTORS AFFECTING DDI
The extent of DDI will depend on the characteristics of the perpetrator and victim drugs involved in the interaction. Perpetrator and victim properties impacting drug interaction risk are summarized in Figure 2.2. For an inhibitor, the greater the unbound inhibitor concentration relative to its potency, the greater is the extent of inhibition. Inhibitor concentrations at any point of time will depend on the dose administered and the organ where the affected enzyme or transporter is located. For a victim of inhibition, the greater its dependence on the inhibited route for its elimination, the greater is the potential for an altered pharmacokinetics of the drug. If more than 70% of a drug is eliminated using the inhibited pathway, the risk for interaction is high (Dunne et al., 2011). Thus, it is important to balance the clearance of a victim drug between hepatic, renal, and biliary routes during the design stage, in order to minimize risk from drug–drug interactions. For a high clearance victim drug that is orally administered, the magnitude of interaction is likely to be high due to first‐pass, making it more sensitive to DDI compared with a low clearance drug. Victim drugs associated with a narrow therapeutic window and high variability are more sensitive to DDI.
Figure 2.2. Perpetrator and victim properties impacting drug interaction risk.
Induction and/or inhibition of drug transporters of the small intestine, liver, and kidney are major determinants of drug–drug interactions. Transporter‐mediated drug–drug interactions in these three organs can considerably influence the pharmacokinetics and clinical effects of drugs. Transporters of interest
